Objective To establish a liver disease refined management platform encompassing hepatocellular carcinoma(HCC)screening for high-risk populations,longitudinal patient follow-up management,multidisciplinary team(MDT)consulta-tions for complex cases,and intelligent data analysis.This platform aims to achieve early detection and standardized management of individuals at risk of HCC,thereby improving the rates of curative treatment and patient survival.Methods Standardized data interfaces were utilized to integrate diverse medical data,including electronic health records,laboratory test results,and imaging reports.Multiple HCC risk assessment models were applied to assist clinicians in patient risk stratification and diagnosis.For un-diagnosed patients,personalized follow-up programs were implemented according to their risk categories.Clinical information of patients requiring MDT discussions was systematically collated to support comprehensive case evaluations.Results After the platform's introduction,a total of 6 187 patients were enrolled,accounting for 23.2％of outpatient attendees.The number of MDT discussions reached 351,representing a 46.3％year-on-year increase.The outcomes demonstrated significant improvements in the quality of liver disease management and diagnostic processes.Conclusion The platform can effectively achieve precise stratification of HCC risk groups,providing significant support for the early detection,diagnosis,and treatment of high-risk indi-viduals.Additionally,it offers a digital solution for facilitating the full-cycle precision management of liver disease patients,from screening to diagnosis treatment and follow-up.

Objective To establish a liver disease refined management platform encompassing hepatocellular carcinoma(HCC)screening for high-risk populations,longitudinal patient follow-up management,multidisciplinary team(MDT)consulta-tions for complex cases,and intelligent data analysis.This platform aims to achieve early detection and standardized management of individuals at risk of HCC,thereby improving the rates of curative treatment and patient survival.Methods Standardized data interfaces were utilized to integrate diverse medical data,including electronic health records,laboratory test results,and imaging reports.Multiple HCC risk assessment models were applied to assist clinicians in patient risk stratification and diagnosis.For un-diagnosed patients,personalized follow-up programs were implemented according to their risk categories.Clinical information of patients requiring MDT discussions was systematically collated to support comprehensive case evaluations.Results After the platform's introduction,a total of 6 187 patients were enrolled,accounting for 23.2％of outpatient attendees.The number of MDT discussions reached 351,representing a 46.3％year-on-year increase.The outcomes demonstrated significant improvements in the quality of liver disease management and diagnostic processes.Conclusion The platform can effectively achieve precise stratification of HCC risk groups,providing significant support for the early detection,diagnosis,and treatment of high-risk indi-viduals.Additionally,it offers a digital solution for facilitating the full-cycle precision management of liver disease patients,from screening to diagnosis treatment and follow-up.

Lingguizhugan Decoction (LGZG) has been investigated in basic studies, with satisfactory effects on insulin resistance in non-alcoholic fatty liver disease (NAFLD). This translational approach aimed to explore the effect and underlying mechanism of LGZG in clinical setting. A randomized, double-blinded, placebo-controlled trial was performed. A total of 243 eligible participants with NAFLD were equally allocated to receive LGZG (two groups: standard dose and low dose) or placebo for 12 weeks on the basis of lifestyle modifications. The primary efficacy variable was homeostasis model assessment of insulin resistance (HOMA-IR). Analyses were performed in two populations in accordance with body mass index (BMI; overweight/obese, BMI ⩾ 24 kg/m²; lean, BMI < 24 kg/m²). For overweight/obese participants, low-dose LGZG significantly decreased their HOMA-IR level compared with placebo (-0.19 (1.47) versus 0.08 (1.99), P = 0.038). For lean subjects, neither dose of LGZG showed a superior effect compared with placebo. Methylated DNA immunoprecipitation sequencing and real-time qPCR found that the DNA N6-methyladenine modification levels of protein phosphatase 1 regulatory subunit 3A (PPP1R3A) and autophagy related 3 (ATG3) significantly increased after LGZG intervention in overweight/obese population. Low-dose LGZG effectively improved insulin resistance in overweight/obese subjects with NAFLD. The underlying mechanism may be related to the regulation of DNA N6-methyladenine modification of PPP1R3A and ATG3. Lean subjects may not be a targeted population for LGZG.
Humans ; Non-alcoholic Fatty Liver Disease/drug therapy* ; Overweight/drug therapy* ; Insulin Resistance ; Obesity/drug therapy* ; China ; DNA/therapeutic use*